HNF-3γ Inhibitors

The chemical class known as HNF-3γ inhibitors comprises a group of compounds that can either directly or indirectly hinder the activity of HNF-3γ, a transcription factor involved in various cellular processes. These inhibitors influence HNF-3γ-mediated functions by targeting specific biochemical and cellular pathways. Curcumin, for instance, indirectly inhibits HNF-3γ through its action on the NF-κB pathway, which subsequently affects HNF-3γ expression and function within NF-κB-associated processes. Wortmannin acts indirectly by targeting the PI3K/Akt pathway, leading to altered HNF-3γ activity. Niclosamide disrupts Wnt/β-catenin signaling, indirectly affecting HNF-3γ function within this context. Rapamycin indirectly inhibits HNF-3γ through mTOR inhibition, impacting HNF-3γ activity within relevant pathways. AG490, on the other hand, indirectly inhibits HNF-3γ by blocking JAK/STAT signaling, which influences HNF-3γ expression and function. LY294002 indirectly inhibits HNF-3γ through PI3K inhibition, modulating HNF-3γ activity within cellular processes.

Additionally, SB203580 indirectly inhibits HNF-3γ by targeting the p38 MAPK pathway, which influences HNF-3γ expression and function. ICG-001 inhibits HNF-3γ indirectly through the Wnt/β-catenin pathway, altering HNF-3γ activity within this context. PD98059 indirectly inhibits HNF-3γ by dampening the MAPK/ERK pathway, affecting HNF-3γ expression and function. SB431542 inhibits HNF-3γ indirectly by blocking the TGF-β pathway, leading to altered HNF-3γ activity. CAY10512 indirectly inhibits HNF-3γ through the inhibition of the PI3K/Akt pathway, impacting HNF-3γ-mediated processes. Lastly, BMS-754807 indirectly inhibits HNF-3γ by targeting the IGF-1R pathway, modulating HNF-3γ function within this context.